CE3F4 manufacturers
- CE3F4
-
- $47.00
-
2026-07-15
- CAS:143703-25-7
- Purity: 98.06%
- Supply Ability: 10g
- CE3F4
-
- $47.00
-
2026-07-15
- CAS:143703-25-7
- Purity: 98.06%
- Supply Ability: 10g
|
| Product Name: | CE3F4 | | Synonyms: | CE3F4;5,7-Dibromo-6-fluoro-3,4-dihydro-2-methyl-1(2H)-quinolinecarboxaldehyde;1(2H)-Quinolinecarboxaldehyde, 5,7-dibromo-6-fluoro-3,4-dihydro-2-methyl-;CE3F4 >=98% (HPLC);inhibit,Inhibitor,CE3F4,CE-3F4;5,7-dibromo-6-fluoro-2-methyl-1,2,3,4-tetrahydroquinoline-1-carbaldehyde;CE3F4, 10 mM in DMSO;5,7-Dibromo-6-fluoro-2-methyl-3,4-dihydroquinoline-1(2H)-carbaldehyde | | CAS: | 143703-25-7 | | MF: | C11H10Br2FNO | | MW: | 351.01 | | EINECS: | | | Product Categories: | | | Mol File: | 143703-25-7.mol |  |
| | CE3F4 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO > 10 mM | | form | Powder | | color | White to off-white | | InChI | InChI=1S/C11H10Br2FNO/c1-6-2-3-7-9(15(6)5-16)4-8(12)11(14)10(7)13/h4-6H,2-3H2,1H3 | | InChIKey | ZZLQPWXVZCPUGC-UHFFFAOYSA-N | | SMILES | N1(C=O)C2=C(C(Br)=C(F)C(Br)=C2)CCC1C |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Aquatic Chronic 2 |
| | CE3F4 Usage And Synthesis |
| Uses | CE3F4 has been used as a selective exchange protein directly activated by cAMP isoform 1 (Epac1) inhibitor in cell proliferation assay to study the influence of Epac type I on cell proliferation of C6 cells (a model of glioma). | | Biological Activity | CE3F4 is a tetrahydroquinoline derivative th at blocks agonist-stimulated Epac1 (exchange protein directly activated by cAMP isoform 1) guanine nucleotide exchange activity toward its effector Rap1 (IC50 = 23 μM; Epac agonist = 2 μM 8-CPT-2μ-O-Me-cAMP) by targeting agonist-bound Epac1 in an agonist-uncompetitive manner without affecting the GDP exchange on Rap1, Rap1-Epac1 interaction, or PKA type I/II activity (CβRIβ & CαRIIβ). CE3F4 (20 μM) effectively inhbits cellular Rap1 activation upon 10 μM Sp-8-pCPT-2μ-O-Me-cAMPS (Epac1-transfected HEK293 and r at neonatal cardiac myocytes) or 10 μM β-adrenergic receptor agonist isoprenaline stimulation (β1AR & Epac1 dually transfected HEK293). The isolated CE3F4 R enantiomer is reported to display 10-fold Epac1 selectivity over Epac2, and is 10-times more potent than the CE3F S enantiomer against Epac1.', 'Epac1 is a downstream effector of the cyclic adenosine monophosphate (cAMP) pathway. | | in vivo | CE3F4 (1-3 mg/kg; through a catheter in the internal jugular vein) inhibits atrial fibrillation (AF) and CE3F4 (3 mg/kg; i.v.) inhibits ventricular arrhythmias[4].
CE3F4 (10 mg/kg; i.v.) improves cardiac function after myocardial infarction in mice[5]. | Animal Model: | Wild-type (WT) mice (induced AF after 20min of CE3F4 administration)[4] | | Dosage: | 3 mg/kg and 1mg/kg | | Administration: | Through a catheter in the internal jugular vein | | Result: | Shortened the duration of the pacing-induced AF at 3mg/kg.
|
| Animal Model: | Casq2-KO mice (premature ventricular contraction induced by isoproterenol injection 20min after CE3F4 administration)[4] | | Dosage: | 3 mg/kg | | Administration: | I.v. | | Result: | Reduced the incidence of sympathetic activation-induced ventricular arrhythmias.
|
| | storage | Store at -20°C |
| | CE3F4 Preparation Products And Raw materials |
|